RATIO OF TRIGLYCERIDES TO HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND MARKERS OF LIVER INJURY IN DIABETES MELLITUS
Abstract
Objectives: The present study was done to evaluate and compare the triglyceride to high-density lipoprotein (TG/HDL) ratio in subjects with diabetes
mellitus (DM) and diabetic prone subjects (impaired glucose tolerance [IGT]) with normal subjects without diabetes. An attempt was also made to
correlate TG/HDL with markers of liver injury such as alanine aminotransferase, aspartate aminotransferase, (AST), and alkaline phosphatase (ALP).
Methods: Lab data of 496 patients attending Pushpagiri medical health checkup were obtained. The subjects were grouped into DM: (fasting plasma
glucose >126 mg/dl), IGT: (Fasting plasma glucose: 110-126 mg/dl) and normal: (fasting plasma glucose < 110 mg/dl).
Results: Statistically significant difference were observed in levels of TG, low-density lipoprotein (LDL), TG/HDL ratio, AST, ALP between diabetes, IGT
and normal subjects. Statistical significance within the groups was tested using post-hoc Analysis. The level of TG and TG/HDL ratio was significantly
higher in subjects with DM compared to normal subjects. The mean value of total cholesterol and LDL-C was found to be higher in normal subjects
than in DM and IGT. AST, ALP values were found to be significantly higher in subjects with IGT than normal subjects.
Conclusion: From this study, it can be concluded that TG and TG/HDL ratio were high in DM and IGT than subjects with normal plasma glucose. Liver
injury marker enzymes were found to be high in IGT and is correlated with TG/HDL ratio in DM.
Keywords: Diabetes mellitus, Impaired glucose tolerance, Hypertriglyceridemia, Triglyceride to high-density lipoprotein ratio, Markers of liver injury.
Downloads
References
Gopal L, Sharma T. Use of intravitreal injection of triamcinolone
acetonide in the treatment of age-related macular degeneration. Indian
J Ophthalmol 2007;55(6):431-5.
Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the
treatment of retinal diseases. ScientificWorldJournal 2014;2014:989501.
Tewari HK, Sony P, Chawla R, Garg SP, Venkatesh P. Prospective
evaluation of intravitreal triamcinolone acetonide injection in macular
edema associated with retinal vascular disorders. Eur J Ophthalmol
;15(5):619-26.
Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular
oedema treated by intravitreal triamcinolone acetonide. A comparative
nonrandomized study. Br J Ophthalmol 2005;89:321-6.
Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal
triamcinolone acetonide for macular oedema due to central retinal vein
occlusion. Br J Ophthalmol 2002;86(2):247-8.
Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone
acetonide for the treatment of central retinal vein occlusion in young
patients. Retina 2004;24(2):324-7.
Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as
adjunctive treatment of diabetic macular edema. Am J Ophthalmol
;132(3):425-7.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA,
Asian J Pharm Clin Res, Vol 8, Issue 6, 2015, 157-160
Jain et al
Reichel E, et al. Intravitreal triamcinolone for refractory diabetic
macular edema. Ophthalmology 2002;109(5):920-7.
Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of
triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol
;121(1):57-61.
Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF,
Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic
diffuse macular edema: Preliminary results of a prospective controlled
trial. Ophthalmology 2004;111(2):218-24.
Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular
degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J
Ophthalmol 1995;23(4):293-8.
Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone
acetonide in exudative age-related macular degeneration. Retina
;20(3):244-50.
Jonas JB, Kreissig I, Degenring R. Repeated intravitreal injections of
triamcinolone acetonide as treatment of progressive exudative agerelated
macular
degeneration.
Graefes
Arch
Clin Exp Ophthalmol
;240(10):873-4.
Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al.
A randomized clinical trial of a single dose of intravitreal triamcinolone
acetonide for neovascular age-related macular degeneration: One-year
results. Arch Ophthalmol 2003;121(5):667-73.
Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal
reinjection of triamcinolone for exudative age-related macular
degeneration. Arch Ophthalmol 2004;122(2):218-22.
Jonas JB, Söfker A. Intravitreal triamcinolone acetonide for cataract
surgery with iris neovascularization. J Cataract Refract Surg
;28(11):2040-1.
Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of
neovascular iris vessels by intravitreal injection of crystalline cortisone.
J Glaucoma 2001;10(4):284-7.
Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline
cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch
Clin Exp Ophthalmol 2001;239(6):464-5.
Rodriguez ML, Juarez CP, Luna JD. Intravitreal triamcinolone acetonide
injection in blind painful eyes. Intraocular steroids as a treatment for
blind painful red eyes. Eur J Ophthalmol 2003;13(3):292-7.
McCuen BW 2
, Bessler M, Tano Y, Chandler D, Machemer R. The
lack of toxicity of intravitreally administered triamcinolone acetonide.
Am J Ophthalmol 1981;91(6):785-8.
nd
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al.
Safety of an intravitreal injection of triamcinolone: Results from a
randomized clinical trial. Arch Ophthalmol 2004;122(3):336-40.
Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated
intraocular pressure. Aust N Z J Ophthalmol 1999;27(6):431-2.
Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP,
et al. Acute endophthalmitis following intravitreal triamcinolone
acetonide injection. Am J Ophthalmol 2003;136(5):791-6.
Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous
injection: A comprehensive review. Retina 2004;24(5):676-98.
Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS.
Safety and efficacy of intravitreal triamcinolone acetonide for uveitic
macular edema. Ocul Immunol Inflamm 2005;13(2-3):205-12.
Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA.
Intraocular pressure elevation after intravitreal triamcinolone acetonide
injection. Ophthalmology 2005;112(4):593-8.
Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular
inflammation and associated macular edema. Clin Ophthalmol
;3:41-7.
Klein R, Klein BE, Moss SE. Visual impairment in diabetes.
Ophthalmology 1984;91(1):1-9.
Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant
macular edema after intravitreal bevacizumab is responsive to an
intravitreal dexamethasone implant in retinal vein occlusion. Retina
;33(6):1227-31.
Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular
mechanisms. Clin Sci (Lond) 1998;94(6):557-72.
Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R.
Intravitreal triamcinolone acetonide for exudative age related macular
degeneration. Br J Ophthalmol 2003;87(4):462-8.
Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E
Jr. Treatment with intravitreal steroid reduces blood-retinal barrier
breakdown due to retinal photocoagulation. Arch Ophthalmol
;110(8):1155-9.
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E,
Roth M. Corticosteroids inhibit the expression of the vascular
endothelial growth factor gene in human vascular smooth muscle cells.
Eur J Pharmacol 1998;341(2-3):309-15.
Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM.
Triamcinolone acetonide modulates permeability and intercellular
adhesion molecule-1 (ICAM-1) expression of the ECV304 cell
line: Implications for macular degeneration. Clin Exp Immunol
;121(3):458-65.
Floman N, Zor U. Mechanism of steroid action in ocular inflammation:
Inhibition of prostaglandin production. Invest Ophthalmol Vis Sci
;16(1):69-73.
Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin
synthesis by glucocorticoids in human endothelial cells. Endocrinology
;119(1):62-9.
Couch SM, Bakri SJ. Use of triamcinolone during vitrectomy surgery to
visualize membranes and vitreous. Clin Ophthalmol 2008;2(4):891-6.
Vedantham V, Kim R. Intravitreal injection of triamcinolone acetonide
for diabetic macular edema: Principles and practice. Indian J
Ophthalmol 2006;54(2):133-7.
Pickrell A, Harris A, Ngo S, Amireskandari A, Stewart E, Siesky B.
Delivery of intraocular triamcinolone acetonide in the treatment of
macular edema. Pharmaceutics 2012;4(1):230-42.
Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline
cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J
Ophthalmol 2000;84(9):1064-7.
Jonas JB, Kreissig I, Kamppeter B, Degenring RF. Intravitreal
triamcinolone acetonide for the treatment of intraocular edematous and
neovascular diseases. Ophthalmologe 2004;101(2):113-20.
Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal
triamcinolone for treatment of complicated proliferative diabetic
retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol
;40(5):598-604.
Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon
injection of triamcinolone acetonide for diabetic macular edema.
Korean J Ophthalmol 2006;20(4):205-9.
Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA.
Inter-eye difference in exudative age-related macular degeneration with
minimally classic or occult subfoveal neovascularization after unilateral
intravitreal injection of triamcinolone acetonide. Am J Ophthalmol
;139(6):1073-9.
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal
triamcinolone acetonide and intraocular pressure. Am J Ophthalmol
;138(5):740-3.
Park HY, Yi K, Kim HK. Intraocular pressure elevation after
intravitreal triamcinolone acetonide injection. Korean J Ophthalmol
;19(2):122-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.